What is ARTEMIS® T Cell Therapy?
Eureka’s ARTEMIS® T cell therapy is a novel form of cell therapy that incorporates some of the best features of CAR-T and TCR-T therapy while avoiding many of their disadvantages. ARTEMIS® T cells are engineered to combine the high tumor binding specificity and affinity of an antibody and the evolutionary optimized activation and regulatory pathways of a TCR. This design has the potential to mitigate the uncontrolled release of cytokines, reduce T cell exhaustion, and improve T cell infiltration into solid tumors.
Engineered T Cell Therapy
Engineered T cell therapy uses a person’s T cells to fight cancer. T cells play a central role in the human immune system. They protect the body by killing infected cells, activating other immune cells, and regulating the immune response.
Two common forms of T cell therapy are chimeric antigen receptor (CAR) and T cell receptor (TCR) therapy. These therapies involve extracting a patient’s T cells, genetically modifying them to target a specific protein found on cancer cells and infusing them back into the patient where they circulate, target, and kill cancer cells.
For blood cancers such as leukemia and lymphoma, CAR-T therapy has shown remarkable response rates, and in certain cases, the ability to cure. However, CAR-T therapy has been limited by safety risks associated to cytokine release syndrome (CRS) and neurotoxicity, and lack of success in treating solid tumors.
Unlike CAR-T that can only recognize proteins on the cell surface, TCRs have the potential to treat solid-tumors by recognizing tumor-specific proteins inside of cells. When these tumor-specific proteins are broken into fragments, they are presented together with the major histocompatibility complex, or MHC on the cell surface. However, engineered TCRs have a relatively low target binding affinity and safety issues with potentially unknown cross-reactivity.
Which Diseases will Eureka Seek to Treat?
Our most advanced product candidate, ET140203, is an autologous ARTEMIS® T cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer in adults.
ET140203 utilizes Eureka’s proprietary ARTEMIS® T cell platform engineered with a human TCR-mimic (TCRm) antibody targeting alpha fetoprotein (AFP)-peptide/HLA-A2 complex on cancer cells.
What is The Treatment Cycle Like?
The investigational drug is manufactured specifically for an individual patient, using the individual’s own T cells. The treatment process involves collecting a specific set of cells from the individual’s blood, engineering the cells to specifically kill cancer cells, and infusing the cells back into the patient.
Our Clinical Trials
We have initiated a multi-center Phase I/II clinical trial (ARYA-1) for AFP-positive adult HCC patients in the United States.
More information about the study can be found on clinicaltrials.gov. Medical professionals may also email us at firstname.lastname@example.org for more information about study participation.